Smoking Interventions in General Medical Practices

Status Active, not recruiting

Clinical Trial Summary

Primary care physicians can play an important role in reducing tobacco smoking in the population. The general practice is a suitable setting for implementing proactive smoking interventions, because a large proportion of the population can be regularly reached in a favorable psychological state. Further, a trustful interpersonal relationship between the practitioners and their patients is supposed to increase the susceptibility to preventive measures. However, currently general practitioners are not capitalizing this advantage although evidence based treatments are available, which are effective and cost-effective. Outreach programs combining educational and practice-based measures have been found to be effective in engaging practitioners in screening and in giving advice. Computer expert-system and brief counseling interventions, which are based on the Transtheo-retical Model of behavior change (TTM), are promising approaches for the entire population of practitioners and smoking patients. For large scale implementation, data are needed about the degree of integration in every day routine clinical practice that could be achieved by implementing such interventions. Objectives: Evaluating different strategies for the implementation of proactive smoking interventions in general practices. Methods: In a randomized controlled trial, 150 randomly selected general practices of a defined German region will be included. The procedure comprises the implementation of 1) an on-site computer expert-system intervention, 2) a counseling intervention provided by the practitioner, or 3) the computer expert-system plus the counseling intervention. During an implementation phase of one month, two on site training sessions and support by phone will be provided. Routine use of the interventions will be monitored for the following 6 months. Main outcome measures are the number and rate of identified and treated smokers. A follow-up assessment will be realized 12 months after practice attendance to determine the smoking status of the treated smokers.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00679861
Study type	Interventional
Source	University Medicine Greifswald
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 2004
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05176418` - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate	Early Phase 1
Completed	`NCT04084210` - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use	Phase 2
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Withdrawn	`NCT03707600` - State and Trait Mediated Response to TMS in Substance Use Disorder	N/A
Recruiting	`NCT03999099` - Targeting Orexin to Treat Nicotine Dependence	Phase 1
Completed	`NCT03847155` - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery	N/A
Completed	`NCT02840435` - Study on Sit to Quit Phone Intervention	N/A
Completed	`NCT02139930` - Project 2: Strategies for Reducing Nicotine Content in Cigarettes	N/A
Completed	`NCT01982110` - A Mindfulness Based Application for Smoking Cessation	N/A
Completed	`NCT01926626` - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers	Phase 2
Withdrawn	`NCT01569477` - Striving to Quit-Wisconsin Tobacco Quit Line	N/A
Completed	`NCT01569490` - Striving to Quit: First Breath	N/A
Completed	`NCT01632189` - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers	N/A
Completed	`NCT01685996` - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation	Phase 1/Phase 2
Active, not recruiting	`NCT01182766` - New Treatment for Alcohol and Nicotine Dependence	Phase 2/Phase 3
Completed	`NCT00996034` - Nicotine Vaccination and Nicotinic Receptor Occupancy	Phase 2
Completed	`NCT01061528` - Coping Skills Treatment for Smoking Cessation	N/A
Suspended	`NCT01636336` - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects	N/A
Completed	`NCT01943994` - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study	N/A
Withdrawn	`NCT01589081` - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Smoking Interventions in General Medical Practices — PRO GP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms